Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific/Medinol

This article was originally published in The Gray Sheet

Executive Summary

Letter purporting to terminate exclusive, worldwide NIR coronary stent supply agreement with Boston Scientific is "improper and invalid," Boston Scientific says in a March 1 release. Medinol alleges breaches of the supply agreement, which Boston Scientific disputes. While the parties remain embroiled in litigation in New York and Israel with respect to the supply agreement and management of Medinol, Boston Scientific says it will challenge the latest action and "considers the supply agreement to be in full force and effect"...
Advertisement
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT016169

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel